Machine learning predicts cuproptosis-related lncRNAs and survival in glioma patients
View abstract on PubMed
Summary
This summary is machine-generated.This study reveals distinct cuproptosis gene expression patterns in glioblastoma (GBM) and low-grade glioma (LGG). These findings may improve survival prediction for glioma patients.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Gliomas, particularly glioblastoma (GBM), are aggressive central nervous system tumors with poor prognoses despite current treatments.
- Cuproptosis, a copper-driven cell death pathway, presents a novel target distinct from apoptosis and ferroptosis.
- Understanding differential gene expression in glioma subtypes is crucial for developing targeted therapies.
Purpose Of The Study
- To investigate differential expression of cuproptosis-related genes between GBM and LGG.
- To identify enriched pathways associated with cuproptosis gene expression unique to each glioma subtype.
- To develop predictive models for glioma survival status.
Main Methods
- Comparative analysis of cuproptosis-related gene expression in GBM versus LGG datasets.
- Bioinformatic analysis of pathway enrichment for differentially expressed genes.
- Development and validation of survival prediction models using XGBoost and Random Forest algorithms.
- Application of the ROSE algorithm for dataset balancing to enhance model accuracy.
Main Results
- Significant differences in cuproptosis-related gene expression were identified between GBM and LGG.
- Distinct molecular pathways were found to be enriched in GBM and LGG based on exclusive cuproptosis gene expression.
- The developed XGBoost and Random Forest models demonstrated potential for predicting glioma survival status.
Conclusions
- Cuproptosis-related genes exhibit differential expression patterns that distinguish GBM from LGG.
- Pathway analysis highlights distinct molecular mechanisms influenced by cuproptosis in glioma subtypes.
- Predictive models based on cuproptosis genes offer a promising avenue for improving glioma patient prognostication.

